Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1763 - A framework for education and advocacy for optimal cancer pain management in resource-limited settings (506P)


18 Nov 2017


Poster lunch


Mary Bautista


Annals of Oncology (2017) 28 (suppl_10): x155-x165. 10.1093/annonc/mdx676


M.J. Bautista1, S.H. Ahmedzai2, K. Bouzid3, R. Gibson4, Y. Gumara5, A.A.I. Hassan6, S. Hattori7, D. Keefe8, D.C. Kraychete9, D.H. Lee10, K. Tamura11, J.J. Wang12

Author affiliations

  • 1 Benavides Cancer Institute, University of Santo Tomas Hospital, 1008 - Manila/PH
  • 2 Medical Oncology Department, University of Sheffield, Sheffield/GB
  • 3 Medical Oncology Department, Pierre & Marie Curie Center, Algiers/DZ
  • 4 Division Of Health Sciences, University of South Australia, Adelaide/AU
  • 5 National Cancer Center, Dharmais Hospital, Jakarta/ID
  • 6 Supportive & Palliative Care Section, Medical Oncology Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha/QA
  • 7 The Cancer Institute Hospital Of Jfcr, Department of Cancer Pain Management, Tokyo/JP
  • 8 Department Of Medicine, Faculty Of Health Sciences, University of Adelaide, Adelaide/AU
  • 9 College Of Medicine, Federal University of Bahia, Salvador/BR
  • 10 Department Of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul/KR
  • 11 Division Of Oncology, Hematology, And Infectious Diseases, Department Of Medicine, Fukuoka University School of Medicine, Fukuoka/JP
  • 12 Department Of Oncology, Changzheng Hospital, Shanghai/CN


Abstract 1763


Inadequate information on translating guideline recommendations into clinical practice; resource limitations; lack of education of healthcare providers (HCPs)/policymakers/patients are factors contributing to the gap between best practices and actual clinical practice in cancer pain management (CPM). To address these gaps and optimize CPM in resource-limited settings (R-LS), we propose a two-step initiative – the development of practical resource-based CPM algorithms, and an education and advocacy framework to support effective implementation of the algorithms in R-LS.


The CAPER WG–a global, multidisciplinary consortium of oncologists, pain specialists, and palliative care experts–has developed an education and advocacy framework for improving CPM in R-LS, stemming from literature review and a workshop held in February 2017.


We developed CPM algorithms incorporating guideline recommendations and expert opinion, applying a hierarchy of resource-based constraints to provide HCPs a tailored approach to manage patient needs. To support the implementation of these CPM algorithms, we formulated a framework comprising an educational program, pilot implementation, and an advocacy plan. The educational framework provides HCPs with clinically-relevant information, emphasizing the practical element of translating knowledge into practice and illustrating how optimal CPM can be provided despite resource limitations. Pilot implementation studies are essential to demonstrate the effectiveness of the algorithms and the educational program; the results will allow algorithm refinement, optimization of implementation strategies and development of advocacy plans. A strategic advocacy plan is imperative to achieve our ultimate goal of optimizing CPM in R-LS; effective advocacy will drive collaborative and multifaceted efforts amongst key stakeholders to ensure improvement of resource access and availability.


The proposed framework for education and advocacy can guide the translation of our resource-based CPM algorithms into clinical practice in all settings, ultimately providing optimal CPM for all patients despite differential resources.

Clinical trial identification

Legal entity responsible for the study

CAPER Working Group


Mundipharma Pte Ltd


M.J. Bautista: IS a member of the Advisory Board and Expert Panel of Mundipharma Philippines and Mundipharma's Speakers' Bureau; has co-authored international research sponsored by Mundipharma; and has received remunerations for lectures given. S.H. Ahmedzai: has received payments for conducting research, giving educational lectures and taking part in advisory boards with Astra Zeneca, Grunenthal, Kyowa Kirin and Mundipharma. S. Hattori: has served in a advisory role for Terumo Inc, Shionogi Co., and Hisamitsu Co. D.C. Kraychete: serves on the Latin America Board of Grunenthal Group. D.H. Lee: has received honoraria from AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, CJ Healthcare, Eli Lilly, Jansen, Merck, MSD, Mundipharma, Novartis, Ono, Pfizer, Roche, Samyang Biopharm and ST Cube for participating in advisory boards; consulting fees from Ministry of Food and Drug Safety (MFDS) Korea, Health Insurance Review and Assessment Service (HIRA) Korea, National Evidence-based Collaborating Agency (NECA) Korea, and National Cancer Control Planning Board Korea. K. Tamura: has received remunerations for lectures from Kyowa Hakko Kirin Co. Ltd., Ono Pharmaceutical Co. Ltd., Eli Lilly Japan K.K.

All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.